Instructional Courses

Buy courses during registration or login to your account
if you have already registered

  • Friday 08 September
    08:00-10:00

  • IC 12
  • 3D Digital MIVS Vitrectomy and Mechanical Vision 2017: Latest Update wetlab prerequisite

    Thomas Aaberg USA Christopher Riemann USA Athanasios Nikolakopoulos GREECE

  • Course Organisers:
    T. Aaberg USA, C. Riemann USA, A. Nikolakopoulos GREECE


    Faculty

    P. Dugel USA

    S. Rizzo ITALY

    J.A. Pournaras SWITZERLAND

    T.J. Wolfensberger SWITZERLAND

    F. Balta ROMANIA

    S. Gotzardis GREECE

    V. Ferrara ITALY

    K. Kadonosono JAPAN

    M. Figueroa SPAIN

    D. Chow CANADA

    Y. Oshima JAPAN


  • Friday 08 September
    08:00-09:30

  • IC 13
  • Macular Dystrophies wetlab prerequisite

    Guiseppe Querques ITALY Eric Souied FRANCE


    • 08.00
    • G. Querques ITALY
      Best disease

    • 08.10

    • Discussion

    • 08.15

    • C.J. Boon THE NETHERLANDS
      Pattern dystrophies

    • 08.25

    • Discussion

    • 08.30

    • E. Souied FRANCE
      Stargardt disease and FFM

    • 08.40

    • Discussion

    • 08.45

    • C.B Hoyng THE NETHERLANDS
      Macular dystrophies mimicking AMD

    • 08.55

    • Discussion

    • 09.00

    • B.P. Leroy BELGIUM & USA
      Cone dystrophies

    • 09.10

    • Discussion

    • 09.15

    • I. Audo FRANCE
      X-linked reinoschisis

    • 09.25

    • Discussion

    • 09.30

    • End of course

  • IC 14
  • Latest Learnings and Novel Insights in Anti-VEGF Therapy wetlab prerequisite

    Ursula Schmidt-Erfurth AUSTRIA


    • 08.00
    • N. Waheed USA
      Understanding the therapeutic response of CNV by OCT-A

    • 08.15

    • A. Gaudric FRANCE
      Does anti-VEGF restore capillary perfusion in DME

    • 08.30

    • A. Fawzi USA
      Impact of anti-VEGF on ischemia in diabetic retinopathy

    • 08.45

    • G. Staurenghi ITALY
      Is there a benefit from switching substances?

    • 09.00

    • B. Gerendas AUSTRIA
      Predictability of efficacy of anti-VEGF therapy

    • 09.15

    • U. Schmidt-Erfurth AUSTRIA
      Insights from a global real-world use: The LUMINOUS study

    • 09.30

    • End of course

  • IC 15
  • Ocular Oncology 1: Differential Diagnosis of Intraocular Tumours and Pseudo-tumours wetlab prerequisite

    Laurence Desjardins FRANCE Leonidas Zografos SWITZERLAND


    • 08.00
    • A. Schalenbourg SWITZERLAND
      Differential diagnosis of small pigmented choroidal tumours

    • 08.15

    • N. Cassoux FRANCE
      Differential diagnosis of un-pigmented choroidal tumours

    • 08.30

    • V. Cohen UK
      Differential diagnosis of vascular tumours

    • 08.45

    • L. Lumbroso FRANCE
      Differential diagnosis of ciliary body tumours

    • 09.00

    • L. Zografos SWITZERLAND
      Differential diagnosis of tumours and psuedo-tumours of the optic disc

    • 09.15

    • T. Hadjistilianou ITALY
      Differential diagnosis of paediatric intraocular tumours

    • 09.30

    • End of course

  • IC 16
  • The Management of Complex Themes in Vitreoretinal Surgery: Pits & Pitfalls wetlab prerequisite

    Jordi Calzada ITALY Andrea Grosso USA Eric Sigler USA


    • 08.00
    • A. Grosso ITALY
      'Wireless Communication' in vitreoretinal diseases

    • 08.12

    • J. Randolph USA
      2 port reoperation under oil

    • 08.24

    • E. Sigler USA
      Phacovitrectomy: When and for whom management of primary failure in macular hole

    • 08.30

    • G. Querques ITALY
      TBC

    • 08.36

    • M. Fioretto ITALY
      Scleral patch in buckle exposure

    • 08.48

    • M. Romano ITALY
      The depth of traction in the disease of interfaces

    • 09.00

    • L. Arias SPAIN
      Peeling of the ILM in retinal detachment

    • 09.12

    • J. Calzada USA
      Translimbal lensectomy in severe retinal detachment

    • 09.24

    • Discussion

    • 09.30

    • End of course

  • Friday 08 September
    11:00-12:30

  • IC 17
  • Geographic Atrophy Secondary in AMD: Key issues on Diagnosis, Classification & Management wetlab prerequisite

    Frank Holz GERMANY


    • 11.00
    • S. Schmitz-Valckenberg GERMANY
      Terminology, classification and imaging

    • 11.20

    • F. Holz GERMANY
      Markers for geographic atrophy progression?

    • 11.40

    • C. Hoyng THE NETHERLANDS
      Differential diagnosis of geographic atrophy - Pearls & pitfalls

    • 12.00

    • A. Tufail UK
      From intermediate AMD to geographic atrophy

    • 12.15

    • G. Staurenghi ITALY
      Current and future clinical management of geographic atrophy patients

    • 12.30

    • End of course

  • IC 18
  • Phakomatoses wetlab prerequisite

    Laurence Desjardins SWITZERLAND Leonidas Zografos FRANCE


    • 11.00
    • L. Zografos SWITZERLAND
      Introduction and general considerations

    • 11.15

    • E. Midena ITALY
      Neurofibromatosis type 1 and type 2

    • 11.30

    • A. Gaudric FRANCE
      Von Hippel-Lindau disease

    • 11.45

    • N. Cassoux FRANCE
      Tuberous sclerosis of Bourneville

    • 12.00

    • A. Schalenbourg SWITZERLAND
      Sturge-Weber disease

    • 12.15

    • L. Zografos SWITZERLAND
      B. D. B. / W-M Syndrome

    • 12.30

    • End of course


  • IC 19
  • Ocular Oncology 2: Treatment for ocular melanoma wetlab prerequisite

    Serge Leyvraz GERMANY Stefan Seregard SWEDEN


    • 11.00
    • R. Al-Jamal UK
      Treatment of small choroidal lesions

    • 11.15

    • D. Pelayes ARGENTINA
      Biopsy Techniques

    • 11.30

    • J. Folke Kiilgaard DENMARK
      Brachytherapy

    • 11.45

    • S. Seregard SWEDEN
      Uveal melanoma: Should we simply take the eye out?

    • 12.00

    • H. Heimann UK
      How to avoid toxic tumour syndrome

    • 12.15

    • S. Leyvraz GERMANY
      Metastatic uveal melanoma

    • 12.30

    • End of course

  • Friday 08 September
    11:00-13:00

  • IC 20
  • Managing Complications in Vitreoretinal Surgery wetlab prerequisite

    Alistair Laidlaw UK Paul Sullivan UK


    • 11.00
    • P. Sullivan UK
      Complications of scleral buckling

    • 11.18

    • A. Laidlaw UK
      Retinal trauma during vitrectomy

    • 11.36

    • C. Pavesio UK
      Inflammation and infection after vitreoretinal surgery

    • 11.54

    • P. Sullivan UK
      Post vitrectomy cataract

    • 12.12

    • A. Laidlaw UK
      Complications of diabetic vitrectomy

    • 12.30

    • P. Sullivan UK
      Intraocular haemorrhage during vitrectomy

    • 12.48

    • Discussion

    • 13.00

    • End of course

  • Friday 08 September
    14:30-16:00

  • IC 21
  • Management of Proliferative Diabetic Retinopathy wetlab prerequisite

    Moin Mohamed UK Alistair Laidlaw UK


    • 14.30
    • A. Laidlaw UK
      Welcome and introduction

    • 14.40

    • L. Downey UK
      Pathophysiology of PDR

    • 14.50

    • S. Mann UK
      Epidemiology, classification and screening for PDR

    • 15.00

    • M. Mohamed UK
      PRP: When to start, where to do it, how much to do, when to stop

    • 15.10

    • N. Davies UK
      Addressing general medical risk factors

    • 15.15

    • N. Davies UK
      Role of anti-VEGF drugs: Current and future, anterior hyaloid proliferation and rubeosis

    • 15.25

    • R. Wong UK
      Diabetic vitreous haemorrhage: Aetiology and management

    • 15.35

    • A. Laidlaw UK
      Retinal traction from PDR: Aetiology and management

    • 15.45

    • Discussion

    • 16.00

    • End of Course


  • IC 22
  • OCT-Angiography: How to Understand What we See wetlab prerequisite

    Jean-François Korobelnik FRANCE


    • 14.30
    • G. Staurenghi ITALY
      Overview on OCT-A

    • 14.45

    • J. Cunha-Vaz PORTUGAL
      OCT-A in Diabetic Retinopathy

    • 15.00

    • N. Eter GERMANY
      OCT-A in AMD

    • 15.15

    • M.B Rougier FRANCE
      OCT-A and optic disc

    • 15.30

    • J.F Korobelnik FRANCE
      Quantification in OCT-A: What for?

    • 15.45

    • Discussion

    • 16.00

    • End of Session


  • Friday 08 September
    14:30-16:30

  • IC 23
  • Current Management of ROP and Paediatric Vitreo-Retinal Diseases

    George Caputo FRANCE Andres Kychenthal CHILE


    • 14.30
    • M. Trese USA
      Latest developments in paediatric retina

    • 14.45

    • L. Vajzovic USA
      Paediatric rhegmatogenous retinal detachment

    • 15.00

    • M.E. Hartnett USA
      ROP risk factors and screening

    • 15.15

    • W-C. Wu TAIWAN
      Paediatric Vitreo-retinal haemorrhages

    • 15.30

    • A. Kychenthal CHILE
      Management of progressive ROP

    • 15.45

    • G. Caputo FRANCE
      Coats – PFV – FEVR – Schisis

    • 16.00

    • M. Shapiro USA
      Type 1 ROPT, current management

    • 16.15

    • Discussion

    • 16.30

    • End of Course

  • Friday 08 September
    14:30-16:00

  • IC 24
  • Ocular Oncology 3: Ocular Tumours in Children

    Francis Munier SWITZERLAND Norbert Bornfeld GERMANY


    • 14.30
    • B. Muller GERMANY
      Differential diagnosis of retinoblastoma

    • 14.50

    • F. Munier SWITZERLAND
      Clinical advances in the local treatment of retinoblastoma

    • 15.10

    • N. Bornfeld or Collaborator GERMANY
      Uveal Melanoma in children and young adults

    • 15.30

    • P. Temming GERMANY
      Systemic treatment for retinoblastoma and follow-up

    • 15.50

    • Discussion

    • 16.00

    • End of Session


  • IC 25
  • Post-Operative Endophthalmitis

    Christophe Chiquet FRANCE Jan van Meurs NETHERLANDS


    • 14.30
    • P-L Cornut FRANCE
      Microbiological Diagnosis

    • 14.45

    • M. Saleh FRANCE
      New antibiotics in preventive and curative treatment

    • 15.00

    • T. Wolfensberger SWITZERLAND
      Management of endophthalmitis after intravitreal injections

    • 15.15

    • C. Chiquet FRANCE
      Prognostic factors

    • 15.30

    • J. van Meurs NETHERLANDS
      Role of vitrectomy and steroids

    • 15.45

    • P. Montan & M. Kakar SWEDEN
      Prophylaxis

    • 16.00

    • End of Session

  • Friday 08 September
    16:30-18:00

  • IC 26
  • Key issues for OCT and OCT-Angio Interpretation

    Alain Gaudric FRANCE Giovanni Staurenghi ITALY Adnan Tufail UK


    • 16.30
    • G. Staurenghi FRANCE
      Basics of OCT and OCT-A interpretation and nomenclature

      A. The normal retina
      Retinal and choroidal layers on structural OCT
      Retinal and choroidal circulation viewed by OCT-Angio

      B. Examples of OCT and OCT-A Interpretation Drusen
      Retinal and choroidal atrophy
      Retinal angiomatous proliferation

    • 17.00

    • A. Tufail UK
      Neovascular age macular degeneration

      Early diagnosis of CNV
      Vascularized and avascular PED
      Classification of CNV
      OCT and OCT-A assessment of CNV treatment

    • 17.30

    • A. Gaudric FRANCE
      Central serous chorioretinopathy, Macular œdema

      Chronic and atypical CSC.
      Aspects of macular œdema and cystoid maculopathies

    • 18.00

    • End of course

  • IC 27
  • Ophthalmology in the Year 2025: How Automated Detection of Retinal Disease and Artificial Intelligence will Change your Practice Forever

    Reiner Schlingemann NETHERLANDS


    • 16.30
    • R. O. Schlingemann THE NETHERLANDS
      Introduction

    • 16.35

    • S. Boyd CANADA
      How new computing technologies in bioimaging are accelerating our understanding and management of retinal disease

    • 17.00

    • N. S. Hekster THE NETHERLANDS
      How data and analytics are bringing you more to consider about your patients

    • 17.20

    • M. Abramoff USA
      Effects of automated and computer assisted diagnostics on retinal practice

    • 17.45

    • Panel Discussion

    • 18.00

    • End of course

  • IC 28
  • Ocular Oncology 4: Advances in Genetics in Ocular Oncology

    Norbert Bornfeld GERMANY Antonia Joussen GERMANY


    • 16.30
    • R. Van Ginderdeuren BELGIUM
      Genetics of ocular lymphoma

    • 16.48

    • N. Bornfeld GERMANY
      Genetics of choroidal melanoma

    • 17.06

    • D. Lohmann GERMANY
      Genetics of retinoblastoma

    • 17.24

    • A. Joussen GERMANY
      Genetics of vascular tumours

    • 17.42

    • M. Angi ITALY
      Genetics of conjunctival and lid tumours

    • 18.00

    • End of course


  • IC 29
  • Update on Uveitis in Diagnosis & Therapeutic Procedures

    Marion Funk AUSTRIA


    • 16.30
    • E. Miserocchi ITALY
      Update on diagnosis

    • 16.50

    • M. Funk AUSTRIA
      New advances in imaging

    • 17.10

    • M. de Smet SWITZERLAND
      New developments in treatment

    • 17.30

    • C. Tappeiner SWITZERLAND
      Update on paediatric uveitis

    • 17.50

    • Discussion

    • 18.00

    • End of course

EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy